Trending Now
B2Digital Inc (OTCMKTS:BTDG) Sets Up for Big Things Ahead
B2Digital Inc (OTCMKTS:BTDG), an emerging force on the OTC billing itself as the premier development league for the UFC and top pro MMA sports,...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Xeris Pharmaceuticals Inc (NASDAQ:XERS) Receives Fast Track Designation For XP-0863 From...
Xeris Pharmaceuticals Inc (NASDAQ:XERS) recently announced that XP-0863, its innovative developmental treatment for acute repetitive seizures, received fast track designation from the Food and...
MAKE IT MODERN
LATEST REVIEWS
Denison Mines Corp (NYSEAMERICAN: DNN) Gains 50% Ownership of JCU for...
Denison Mines Corp (NYSEAMERICAN: DNN) has gained 50% ownership of JCU Exploration Company. It is pretty excited to complete the acquisition, paying $20.5 million...
MAKE IT MODERN
PERFORMANCE TRAINING
Results from Phase 2 Study of Vupanorsen (AKCEA-ANGPTL3-L (Rx)) by Akcea Therapeutics Inc. (NASDAQ:AKCA)...
As a problem solver and partner, Akcea Therapeutics Inc. (NASDAQ:AKCA) has worked with several healthcare providers over the years. Together they have been advancing...
Ensysce Biosciences Inc. (NASDAQ: ENSC) Completes Part A Of PF614-012 Clinical Study
Ensysce Biosciences Inc. (NASDAQ: ENSC) has announced the completion of part A of the previously announced PF614-102 clinical trial, “A Phase 1b, Randomized, 2-Part...
Genmab (NASDAQ: GMAB) Reports 1H 2021 Revenue of DKK 2.55 Billion Driven by DARZALEX...
Genmab (NASDAQ: GMAB) has announced financial results for 1H 2021 and provided corporate updates.
1H 2021 DARZALEX revenue up 52%
In the first half of 2021,...
Corcept Therapeutics (NASDAQ:CORT) Commences Enrolment In GRATITUDE II Trial For Miricorilant On Treatment of...
Corcept Therapeutics Incorporated (NASDAQ:CORT) has enrolled the first subject in its GRATITUDE II Phase 2 double-blind, randomized, placebo-controlled study of miricorilant in obese patients...
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) Commences ORLADEYO Shipment to US Patients for HAE Attacks Treatment
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) has announced that ORLADEYO™ (berotralstat) has received FDA approval and the company will start shipments to US patients...
MAKE IT MODERN
